Paraneoplastic antigen Ma2 autoantibodies as specific blood biomarkers for detection of early recurrence of small intestine neuroendocrine tumors

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Cui, Tao ^a   Hurtig, Monica ^b   Elgue, Graciela ^a   Li, Su Chen ^a   Veronesi, Giulia ^c   Essaghir, Ahmed ^d   Demoulin, Jean Baptiste ^d   Pelosi, Giuseppe ^e   Alimohammadi, Mohammad ^b   Öberg, Kjell ^b   Giandomenico, Valeria ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d DE DUVE INSTITUTE   (Belgium)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CHROMOGRANIN A; MA2 AUTOANTIBODY; TUMOR MARKER; UNCLASSIFIED DRUG; MA2 ANTIGEN; NERVE PROTEIN; TUMOR ANTIGEN;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CARCINOID; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LIVER METASTASIS; LUNG SMALL CELL CANCER; LUNG TUMOR; LYMPH NODE METASTASIS; MALE; NEUROENDOCRINE TUMOR; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIMARY TUMOR; PROTEIN EXPRESSION; RECURRENCE RISK; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY; SMALL INTESTINE NEUROENDOCRINE TUMOR; TUMOR RECURRENCE; WESTERN BLOTTING; BLOOD; CHEMISTRY; DISEASE FREE SURVIVAL; INTESTINE TUMOR; METHODOLOGY; MIDDLE AGED; PATHOLOGY; RECURRENT DISEASE; SMALL INTESTINE;

ADULT; AGED; ANTIGENS, NEOPLASM; AUTOANTIBODIES; CHROMOGRANIN A; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOPRECIPITATION; INTESTINAL NEOPLASMS; INTESTINE, SMALL; LUNG NEOPLASMS; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; NEUROENDOCRINE TUMORS; RECURRENCE; SENSITIVITY AND SPECIFICITY; SMALL CELL LUNG CARCINOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 78651245684     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016010     Document Type: Article

References (37)

1. Oberg K (2009) Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors). Curr Opin Endocrinol Diabetes Obes 16: 72-78.
2. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, et al. (2008) Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9: 61-72.
3. Klimstra DS, Modlin IR, Adsay NV, Chetty R, Deshpande V, et al. (2010) Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol 34: 300-313.
4. Kloppel G, Perren A, Heitz PU (2004) The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 1014: 13-27.
5. Creutzfeldt W (1996) Carcinoid tumors: development of our knowledge. World J Surg 20: 126-131.
6. Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, et al. (2010) Chromogranin A-biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 17: 2427-2443.
7. Moran CA, Suster S, Coppola D, Wick MR (2009) Neuroendocrine carcinomas of the lung: a critical analysis. Am J Clin Pathol 131: 206-221.
8. Tsuta K, Raso MG, Kalhor N, Liu DD, Wistuba II, et al. (2010) Histologic features of low- and intermediate-grade neuroendocrine carcinoma (typical and atypical carcinoid tumors) of the lung. Lung Cancer.
9. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, et al. (2008) One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26: 3063-3072.
10. Eriksson B, Kloppel G, Krenning E, Ahlman H, Plockinger U, et al. (2008) Consensus guidelines for the management of patients with digestive neuroendocrine tumors-well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology 87: 8-19.
11. Modlin IM, Moss SF, Chung DC, Jensen RT, Snyderwine E (2008) Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst 100: 1282-1289.
12. Welin S, Stridsberg M, Cunningham J, Granberg D, Skogseid B, et al. (2009) Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors. Neuroendocrinology 89: 302-307.
13. Leja J, Essaghir A, Essand M, Wester K, Oberg K, et al. (2009) Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas. Mod Pathol 22: 261-272.
14. Schuller M, Jenne D, Voltz R (2005) The human PNMA family: novel neuronal proteins implicated in paraneoplastic neurological disease. J Neuroimmunol 169: 172-176.
15. Kaltsas G, Androulakis II, de Herder WW, Grossman AB (2010) Paraneoplastic syndromes secondary to neuroendocrine tumours. Endocr Relat Cancer 17: R173-193.
16. Gozzard P, Maddison P (2010) Which antibody and which cancer in which paraneoplastic syndromes? Pract Neurol 10: 260-270.
17. Lleo A, Invernizzi P, Gao B, Podda M, Gershwin ME (2010) Definition of human autoimmunity-autoantibodies versus autoimmune disease. Autoimmun Rev 9: A259-266.
18. Tan KO, Tan KM, Chan SL, Yee KS, Bevort M, et al. (2001) MAP-1, a novel proapoptotic protein containing a BH3-like motif that associates with Bax through its Bcl-2 homology domains. J Biol Chem 276: 2802-2807.
19. Behr R, Sackett SD, Bochkis IM, Le PP, Kaestner KH (2007) Impaired male fertility and atrophy of seminiferous tubules caused by haploinsufficiency for Foxa3. Dev Biol 306: 636-645.
20. Voltz R, Gultekin SH, Rosenfeld MR, Gerstner E, Eichen J, et al. (1999) A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N Engl J Med 340: 1788-1795.
21. Eichmuller SB, Bazhin AV (2007) Onconeural versus paraneoplastic antigens? Curr Med Chem 14: 2489-2494.
22. Stich O, Jarius S, Kleer B, Rasiah C, Voltz R, et al. (2007) Specific antibody index in cerebrospinal fluid from patients with central and peripheral paraneoplastic neurological syndromes. J Neuroimmunol 183: 220-224.
23. Monstad SE, Knudsen A, Salvesen HB, Aarseth JH, Vedeler CA (2009) Onconeural antibodies in sera from patients with various types of tumours. Cancer Immunol Immunother 58: 1795-1800.
24. Hoffmann LA, Jarius S, Pellkofer HL, Schueller M, Krumbholz M, et al. (2008) Anti-Ma and anti-Ta associated paraneoplastic neurological syndromes: 22 newly diagnosed patients and review of previous cases. J Neurol Neurosurg Psychiatry 79: 767-773.
25. Tschernatsch M, Dierkes C, Gerriets T, Hosch J, Stolz E, et al. (2008) Paraneoplastic neurological syndromes in patients with carcinoid. Eur J Neurol 15: 1390-1394.
26. Drozdov I, Kidd M, Nadler B, Camp RL, Mane SM, et al. (2009) Predicting neuroendocrine tumor (carcinoid) neoplasia using gene expression profiling and supervised machine learning. Cancer 115: 1638-1650.
27. Graus F, Dalmou J, Rene R, Tora M, Malats N, et al. (1997) Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol 15: 2866-2872.
28. Pujol JL, Godard AL, Jacot W, Labauge P (2007) Spontaneous complete remission of a non-small cell lung cancer associated with anti-Hu antibody syndrome. J Thorac Oncol 2: 168-170.
29. Honnorat J, Cartalat-Carel S, Ricard D, Camdessanche JP, Carpentier AF, et al. (2009) Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry 80: 412-416.
30. Syrigos KN, Konstantoulakis MM, Fyssas I, Katsilambros N, Golematis BC (1996) Autoantibodies against insulin and beta-islet cells in pancreatic adenocarcinoma: a possible explanation for diabetes mellitus. Int J Cancer 66: 624-626.
31. Jiang B, Ren T, Dong B, Qu L, Jin G, et al. (2010) Peptide mimic isolated by autoantibody reveals human arrest defective 1 overexpression is associated with poor prognosis for colon cancer patients. Am J Pathol 177: 1095-1103.
32. Dong J, Zeng BH, Xu LH, Wang JY, Li MZ, et al. (2010) Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma. J Transl Med 8: 81.
33. Lenth RV (2007) Statistical power calculations. J Anim Sci 85: E24-29.
34. Rosner B, Grove D (1999) Use of the Mann-Whitney U-test for clustered data. Stat Med 18: 1387-1400.
35. Soreide K (2009) Receiver-operating characteristic curve analysis in diagnostic, prognostic and predictive biomarker research. J Clin Pathol 62: 1-5.
36. Ludbrook J, Royse AG (2008) Analysing clinical studies: principles, practice and pitfalls of Kaplan-Meier plots. ANZ J Surg 78: 204-210.
37. van Dijk PC, Jager KJ, Zwinderman AH, Zoccali C, Dekker FW (2008) The analysis of survival data in nephrology: basic concepts and methods of Cox regression. Kidney Int 74: 705-709.